Hemab Therapeutics/X
Sep 2, 2025, 12:50
New COO at Hemab Therapeutics: Anant Murthy to Advance Rare Blood Disorder Treatments
Hemab Therapeutics posted on X:
”Hemab is growing fast, and we’re thrilled to announce our new Chief Operating Officer, Anant Murthy, PhD.
In this new role, Dr. Murthy will lead the company’s global efforts in market access, launch, and commercialization, bringing Hemab’s promising pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other neglected blood clotting disorders with high unmet needs to patients worldwide.
Read more here.”
Stay updated with Hemostasis Today.
-
Nov 16, 2025, 19:46Ayodeji Olayanju: Academics Blood Matter Too!
-
Nov 16, 2025, 19:30Thomas Reiser Congratulates Saskia Middeldorp on Delivering the 2025 Sol Sherry Distinguished Lecture in Thrombosis
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron